The AMSP drug safety program: methods and global results.
The AMSP (Arzneimittelsicherheit in der Psychiatry) study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions of routine clinical treatment. It developed out of the preceding drug surveillance study AMUP (Arzneimittelüberwachung in der Psychiatrie). Currently 35 hospitals participate in the study. This paper describes the methods of the AMSP, gives detailed definitions of ADRs assessed to be "severe," and discusses the implications of these definitions and the methodological approach for evaluating the AMSP data. In addition, some overall data compiled on ADR rates from 1993 to 2000 are given.
Grohmann
R
R
Department of Psychiatry, Ludwig-Maximilians University of Munich, Munich, Germany. Renate.Grohmann@med.uni-muenchen.de
Engel
R R
RR
Rüther
E
E
Hippius
H
H
D016907:Adverse Drug Reaction Reporting Systems; D001927:Brain Diseases / Q000188:drug therapy / Q000503:physiopathology; D006764:Hospitals, Community; D006778:Hospitals, Psychiatric; D006783:Hospitals, State; D006785:Hospitals, University; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000503:physiopathology; D011358:Product Surveillance, Postmarketing; D011600:Psychopharmacology; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use
D011619:Psychotropic Drugs